Earnings summaries and quarterly performance for IOVANCE BIOTHERAPEUTICS.
Executive leadership at IOVANCE BIOTHERAPEUTICS.
Frederick Vogt
Detailed
Interim Chief Executive Officer and President
CEO
CR
Corleen Roche
Detailed
Chief Financial Officer
DK
Daniel Kirby
Detailed
Chief Commercial Officer
FG
Friedrich Graf Finckenstein
Detailed
Chief Medical Officer
IB
Igor Bilinsky
Detailed
Chief Operating Officer
RP
Raj Puri
Detailed
Chief Regulatory Officer
Board of directors at IOVANCE BIOTHERAPEUTICS.
Research analysts who have asked questions during IOVANCE BIOTHERAPEUTICS earnings calls.
Asthika Goonewardene
Truist Securities
5 questions for IOVA
Also covers: ALLO, AUTL, BNTX +9 more
DD
David Dai
UBS Group AG
5 questions for IOVA
Also covers: IMCR, KURA, SMMT +2 more
RB
Reni Benjamin
Citizens JMP Securities
5 questions for IOVA
Also covers: ALLO, BCAB, BGNE +7 more
TV
Tyler Van Buren
TD Cowen
5 questions for IOVA
Also covers: ADVM, ALLO, ARGX +13 more
YZ
Yanan Zhu
Wells Fargo Securities
5 questions for IOVA
Also covers: ADAP, AFMD, ARCT +13 more
Andrew Tsai
Jefferies
4 questions for IOVA
Also covers: ARQT, ATAI, ATHA +16 more
CK
Colleen Kusy
Robert W. Baird & Co.
4 questions for IOVA
Also covers: APLS, BPMC, CHRS +6 more
PL
Peter Lawson
Barclays PLC
4 questions for IOVA
Also covers: ADAP, ARVN, BPMC +15 more
SS
Salim Syed
Mizuho Securities
4 questions for IOVA
Also covers: AUTL, BBIO, CYTK +6 more
AN
Andrea Newkirk
Goldman Sachs
3 questions for IOVA
Also covers: ABCL, ALKS, ARWR +9 more
BB
Benjamin Burnett
Stifel, Nicolaus & Company, Incorporated
2 questions for IOVA
Also covers: AXSM, PGEN, PRAX +2 more
ED
Etzer Darout
BMO Capital Markets
2 questions for IOVA
Also covers: ARVN, CTMX, EXEL +7 more
Linda Tsai
Jefferies
1 question for IOVA
Also covers: ADC, AKR, AMH +32 more
MG
Mara Goldstein
Mizuho
1 question for IOVA
Also covers: FATE, SNSS, XNCR
Michael Yee
Jefferies
1 question for IOVA
Also covers: ABBV, ALLO, AMGN +19 more
Nick
Virtue Capital
1 question for IOVA
Also covers: ARE, ARGX, FRST +1 more
NL
Nick Lorusso
TD Cowen
1 question for IOVA
Also covers: DAWN, KNSA, TLX
YX
Yanan Xu
Wells Fargo
1 question for IOVA
Recent press releases and 8-K filings for IOVA.
Iovance Biotherapeutics Reports Strong Q4 and Full Year 2025 Revenue Growth, Amtagvi Momentum, and Pipeline Expansion
IOVA
Earnings
Revenue Acceleration/Inflection
Product Launch
- Iovance Biotherapeutics reported total revenue of $264 million for the full year 2025, achieving 30% revenue growth in Q4 2025, driven by Amtagvi.
- The company improved its gross margin from cost of sales to 50% in Q4 2025 and extended its cash runway into the third quarter of 2027.
- Amtagvi is gaining positive commercial traction, with increasing demand, and is expected to reach $1 billion-plus U.S. sales at peak in melanoma alone.
- Lifileucel received Fast Track designation for non-small cell lung cancer, with a potential launch in H2 2027, and demonstrated an unprecedented 50% confirmed response rate in advanced soft tissue sarcomas, with a registrational trial planned.
4 days ago
Iovance Biotherapeutics Reports Strong Q4 and Full Year 2025 Results, Highlights Pipeline Progress
IOVA
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Iovance Biotherapeutics reported full year 2025 total revenue of $264 million, a 61% increase over the prior year, driven by 112% year-over-year Amtagvi revenue growth, and ended 2025 with approximately $303 million in cash, extending its cash runway into the third quarter of 2027.
- The company achieved a 50% margin from cost of sales in Q4 2025 and anticipates remarkable revenue growth in 2026, with Amtagvi and Proleukin having the potential to reach $1 billion-plus U.S. sales at peak.
- The FDA granted Fast Track designation for lifileucel in previously treated non-squamous non-small cell lung cancer, with a potential accelerated approval and launch in the second half of 2027.
- Positive early data for lifileucel in previously treated advanced soft tissue sarcomas demonstrated an unprecedented 50% confirmed response rate, leading to plans for a single-arm registrational trial.
4 days ago
Iovance Biotherapeutics Reports Strong Q4 and Full-Year 2025 Results, Highlights AMTAGVI Growth and Pipeline Progress
IOVA
Earnings
Revenue Acceleration/Inflection
Product Launch
- Iovance Biotherapeutics reported total revenue of $264 million for the full year 2025, within guidance, with Q4 2025 product revenue at $87 million, marking approximately 30% growth from the prior quarter, primarily driven by AMTAGVI. The company also achieved a 50% gross margin from cost of sales in Q4 2025 and extended its cash runway into Q3 2027 with approximately $303 million cash at year-end 2025.
- AMTAGVI is projected to reach over $1 billion in peak U.S. sales for melanoma alone, with the non-small cell lung cancer opportunity being seven times larger and soft tissue sarcoma offering significant additional potential. The FDA granted Fast Track designation for lifileucel in non-squamous non-small cell lung cancer, targeting a potential accelerated approval and launch in H2 2027, and positive early data showed an unprecedented 50% confirmed response rate for lifileucel in advanced soft tissue sarcomas.
4 days ago
Iovance Biotherapeutics Reports Strong Q4 and Full Year 2025 Results and Pipeline Progress
IOVA
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Iovance Biotherapeutics reported Q4 2025 total product revenue of ~$87 million, reflecting ~30% quarterly revenue growth over the prior quarter, and achieved its full year 2025 revenue guidance of ~$264 million.
- The company's gross margin increased to ~50% in Q4 2025.
- As of December 31, 2025, Iovance held a cash position of ~$303 million, which is expected to fund operations into the third quarter of 2027.
- The U.S. FDA granted Fast Track Designation for lifileucel for second-line advanced non-small cell lung cancer, with a potential launch in the second half of 2027.
- Amtagvi received approval in Canada in August 2025, and regulatory submissions are currently under review in the United Kingdom, Australia, and Switzerland.
4 days ago
IOVANCE BIOTHERAPEUTICS Reports Strong 2025 Financials and Provides Pipeline Updates
IOVA
Earnings
Guidance Update
Product Launch
- IOVANCE BIOTHERAPEUTICS achieved Full Year 2025 revenue of ~$264M, meeting its guidance of $250M-$300M, with a Q4 2025 gross margin of 50%.
- The company reported a cash position of $303M as of December 31, 2025, providing a cash runway into Q3 2027.
- AMTAGVI (lifileucel), the first and only approved treatment in 2L+ advanced melanoma, demonstrated ~30% quarterly revenue growth in Q4 2025 and showed a 44% objective response rate (ORR) in real-world data.
- The company's pipeline includes lifileucel for NSCLC, which has Fast Track Designation from the U.S. FDA with a potential launch in 2H27, and a Phase 2 registrational trial for advanced soft tissue sarcomas is set to commence in 2Q 2026.
4 days ago
Iovance Biotherapeutics Announces Positive Early Data for Lifileucel in Advanced Sarcomas
IOVA
New Projects/Investments
- Iovance Biotherapeutics announced positive early data from a pilot clinical trial of lifileucel in patients with advanced undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS).
- The trial demonstrated a 50% Objective Response Rate (ORR) by RECIST v1.1 among the first six evaluable patients, who had advanced disease and were refractory to prior therapy.
- Based on these results, Iovance plans to commence a single arm registrational trial in second-line advanced UPS and DDLPS in the second quarter of 2026 and will engage with the FDA for an accelerated approval path.
- UPS and DDLPS are aggressive soft tissue sarcomas impacting more than 8,000 patients annually in the U.S. and Europe, representing a significant unmet medical need.
4 days ago
AlphaTON Capital Executes Option Agreement to Sell iOx Therapeutics
IOVA
M&A
New Projects/Investments
- AlphaTON Capital Corp. (ATON) has executed a binding call option agreement with Immunova, LLC, granting Immunova the option to acquire iOx Therapeutics Limited, a wholly owned subsidiary of AlphaTON.
- Upon exercise of the option, AlphaTON would be entitled to an upfront cash payment, 10% equity of the acquiring entity, milestone payments potentially exceeding $100 million, and single-digit royalties on future net sales.
- iOx's lead candidate, PORT-2 (IMM60), a liposomal iNKT cell agonist, has been evaluated in advanced melanoma and metastatic NSCLC patients in Phase 1/2 studies, showing biomarker evidence of immune activation and preliminary anti-tumor activity.
- AlphaTON Capital plans to continue advancing its mesothelioma program (TT-4) and is progressing a new Telegram-oriented, AI-driven biotech initiative for rare cancers.
Feb 17, 2026, 8:15 PM
Iovance Biotherapeutics Announces Positive Real-World Data for Amtagvi in Advanced Melanoma
IOVA
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Iovance Biotherapeutics announced real-world data for its commercial product Amtagvi® (lifileucel), the first one-time T cell therapy for solid tumor cancer, demonstrating a best-in-class profile in patients with advanced melanoma.
- In a real-world retrospective study of 41 evaluable patients, Amtagvi achieved a physician-assessed confirmed objective response rate (ORR) of 44% and a disease control rate of 73%.
- The real-world ORR of 44% improved upon the 31% ORR from the C-144-01 clinical trial that supported its February 2024 FDA accelerated approval, with a 52% ORR observed in patients treated earlier (two or fewer lines of therapy).
Feb 5, 2026, 10:15 PM
Iovance Biotherapeutics' Market Sees Significant Growth Projections
IOVA
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- The global autologous cell therapy market was valued at $10.12 billion in 2024 and is projected to reach $44.55 billion by 2033, growing at a CAGR of 17.90% from 2025 to 2033.
- In February 2024, the FDA approved Iovance Biotherapeutics' Amtagvi (lifileucel) for advanced melanoma, marking the first autologous cell therapy supported for a solid tumor.
- North America accounts for over 44% of the global autologous cell therapy market, with the U.S. market alone projected to surpass $17.14 billion by 2034.
- Hospitals and clinics are central to the market, capturing over 47% and expected to administer more than 60% of autologous cell therapies by 2025.
Jan 27, 2026, 6:43 PM
Iovance Biotherapeutics Reiterates FY2025 Revenue Guidance and Provides Clinical Updates
IOVA
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Iovance Biotherapeutics, Inc. expects to achieve its full-year 2025 revenue guidance range of $250 to $300 million in the first full calendar year of Amtagvi sales.
- As of September 30, 2025, the company reported a cash position of $307 million, which is expected to fund operations into Q2 2027.
- Amtagvi, the first FDA-approved one-time T-cell therapy for a solid tumor cancer, has demonstrated a ~50% response rate in real-world patients with previously treated advanced melanoma.
- Clinical trials for Lifileucel in non-small cell lung cancer (NSCLC) showed an Objective Response Rate (ORR) of 25.6% in the IOV-LUN-202 study and 64.3% ORR in the IOV-COM-202 Cohort 3A for ICI-naïve NSCLC, with median Duration of Response (mDOR) not reached in either study.
Jan 9, 2026, 12:35 PM
Quarterly earnings call transcripts for IOVANCE BIOTHERAPEUTICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more